Risk factors that limit use of oral JAK inhibitors in chronic hand eczema: Findings from the Danish Skin Cohort
Most CHE patients have risk factors limiting appropriateness of oral JAKi use. Health care providers should assess risk factors in their patients when choosing treatment for CHE.
Authors
- Simon Francis Thomsen (ORCID: https://orcid.org/0000-0003-1575-9629)
- Alexander Egeberg (ORCID: https://orcid.org/0000-0001-8257-1816)
- Jacob Pontoppidan Thyssen (ORCID: https://orcid.org/0000-0003-3770-1743)
- Andrea Chiricozzi (ORCID: https://orcid.org/0000-0002-6739-0387)
- Y.M.F. Andersen (ORCID: https://orcid.org/0000-0001-6131-2815)
- Lea K. Nymand (ORCID: https://orcid.org/0000-0001-7202-0607)
- Johan Sieborg (ORCID: https://orcid.org/0000-0002-8221-4760)
- Tiago Torres
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Universidade do Porto (PT)
- Bispebjerg Hospital (DK)
- Agostino Gemelli University Polyclinic (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Centro Hospitalar do Porto (PT)
Publication Details
- Journal
- JAAD International
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1016/j.jdin.2024.08.006
- Citations
- 10
- Primary Topic
- Contact Dermatitis and Allergies
- Type
- article
- Field-Weighted Citation Impact
- 5.35
Funders
- Amgen
- Bristol-Myers Squibb
- National Psoriasis Foundation
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Celgene
- Regeneron Pharmaceuticals
- Mylan
- Horizon Therapeutics
- Coloplast
- Kongelig Hofbuntmager Aage Bangs Fond
- Galderma
- Simon Spies Fonden
- Symphogen
- LEO Pharma
- Samsung
- Sanofi Genzyme
- Janssen Pharmaceuticals
- UCB Pharma